Human LILRB1/CD85j/ILT2, C-His, Flag Tag (ECD) Protein
cat.: HA210718
Product name: Human LILRB1/CD85j/ILT2, C-His, Flag Tag (ECD)
Catalog No.: HA210718
Bio-Activity: Testing in progress.
Purity: >95% as determined by SDS-PAGE.
Endotoxin: Less than 1.0 EU per μg by the LAL method.
Formulation: Lyophilized from a 0.2 μm filtered solution of PBS, pH7.4, 5% Trehalose, 5% mannitol.
Background: Receptor for class I MHC antigens. Recognizes a broad spectrum of HLA-A, HLA-B, HLA-C, HLA-G and HLA-F alleles. Receptor for H301/UL18, a human cytomegalovirus class I MHC homolog. Ligand binding results in inhibitory signals and down-regulation of the immune response. Engagement of LILRB1 present on natural killer cells or T-cells by class I MHC molecules protects the target cells from lysis. Interaction with HLA-B or HLA-E leads to inhibition of FCER1A signaling and serotonin release. Inhibits FCGR1A-mediated phosphorylation of cellular proteins and mobilization of intracellular calcium ions. Recognizes HLA-G in complex with B2M/beta-2 microglobulin and a nonamer self-peptide. Upon interaction with peptide-bound HLA-G-B2M complex, triggers secretion of growth-promoting factors by decidual NK cells. Reprograms B cells toward an immune suppressive phenotype.
Source: HEK293
Storage: Please avoid repeated freeze-thaw cycles. Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃ It is recommended that aliquot the reconstituted solution to minimize freeze-thaw cycles.
Reconstitution: Reconstitute at 250 μg/ml in sterile water.
Images
HA210718_1.jpg Fig1: Protein on SDS-PAGE under reducing (R) condition.
Note: All products are “FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE”.